| 000 | 01632 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250517001100.0 | ||
| 264 | 0 | _c20150326 | |
| 008 | 201503s 0 0 hun d | ||
| 022 | _a0030-6002 | ||
| 024 | 7 |
_a10.1556/OH.2014.30031 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSzegedi, Márta | |
| 245 | 0 | 0 |
_a[Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary]. _h[electronic resource] |
| 260 |
_bOrvosi hetilap _cNov 2014 |
||
| 300 |
_a1735-41 p. _bdigital |
||
| 500 | _aPublication Type: English Abstract; Journal Article; Review | ||
| 650 | 0 | 4 |
_aCompassionate Use Trials _xeconomics |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 |
_aEnzyme Replacement Therapy _xeconomics |
| 650 | 0 | 4 |
_aFabry Disease _xdrug therapy |
| 650 | 0 | 4 |
_aFinancing, Government _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aGaucher Disease _xdrug therapy |
| 650 | 0 | 4 |
_aGlycogen Storage Disease Type II _xdrug therapy |
| 650 | 0 | 4 | _aHealth Services Needs and Demand |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHungary |
| 650 | 0 | 4 | _aInsurance Coverage |
| 650 | 0 | 4 | _aInsurance, Health |
| 650 | 0 | 4 |
_aMucopolysaccharidosis I _xdrug therapy |
| 650 | 0 | 4 |
_aMucopolysaccharidosis II _xdrug therapy |
| 650 | 0 | 4 |
_aOrphan Drug Production _xeconomics |
| 650 | 0 | 4 |
_aRare Diseases _xdrug therapy |
| 700 | 1 | _aMolnár, Mária Judit | |
| 700 | 1 | _aBoncz, Imre | |
| 700 | 1 | _aKosztolányi, György | |
| 773 | 0 |
_tOrvosi hetilap _gvol. 155 _gno. 44 _gp. 1735-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1556/OH.2014.30031 _zAvailable from publisher's website |
| 999 |
_c24305613 _d24305613 |
||